Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2016

View Archived Issues

Avacta enters research collaboration with Memorial Sloan Kettering Cancer Center

NIH funding to support Qrono's development of QARRUS platform

Nitto Denko initiates phase I trials in Japan for sublingual seasonal influenza HA vaccine

Celgene offers overview of third quarter 2016

[177-Lu]Pentixather-based endoradiotherapy in xenograft models of leukemia

Umecrine Cognition reports phase I results on GR-3027

Researchers present phase II data for maribavir for treatment of cytomegalovirus infections

Aclaris Therapeutics submits IND to begin study of ATI-50001

Rebiotix's RBX-2660 effective in phase IIb trial for recurrent Clostridium difficile infection

AbbVie presents key events from the third quarter 2016

Intravenous zanamivir shows potential for severe influenza in pediatric patients

ProMIS identifies five antibody candidates with desired target profile for Alzheimer's

Albireo and Biodel complete share exchange to form combined company

KemPharm appeals FDA's CRL for Apadaz

Immunovaccine's DepoVax-formulated neoepitopes show promise in preclinical studies

ReVance Therapeutics initiates phase II trial of RT-002 in plantar fasciitis

Astellas Pharma recaps key events of second quarter of fiscal 2016

Actelion obtains exclusive option to in-license vamorolone

Bio-Path Holdings' BP-1001 awarded orphan drug status from EMA

Prana offers regulatory update on PBT-2 for Huntington's disease

ARTES Biotechnology and BioSun Pharmed collaborate on HPV vaccine in Iran

Takeda offers pipeline update for second quarter of fiscal 2016

Immunocytokine cergutuzumab amunaleukin accumulation evaluated with PET in phase I study

Galapagos describes novel GPR84 antagonists

Innocoll updates progress of Cogenzia, Xaracoll and Collaguard programs

Nordic Nanovector announces progress of phase I/II trial of Betalutin

FORMA Therapeutics discovers new histone deacetylase inhibitors

Committee recommends continuation of Atox Bio's phase III ACCUTE study

Merck KGaA presents novel activin receptor-like kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...